Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

Toxic multinodular goiter medical therapy

Introduction

Overview

Overview

The mainstay of treatment for Toxic multinodular goiter is Surgery. Patients with symptomatic hyperthyroidism, sub-clinical hyperthyroid patients with expected compilations and patients refusing surgical therapy are treated with beta blockers and anti-thyroid pharmacological groups.

Medical Therapy

Medical Therapy

Indications

Symptomatic therapy for toxic multinodular goiter (TMG) is recommended for the patients with the following:[1][2][3]

Pharmacological drug therapy

Following are drugs used in the symptomatic management of toxic multinodular goiter:

Following are antithyroid medicines used in the management of TMG:

Anti-thyroid therapy for toxic multinodular goiter (TMG) is recommended for the patients with the following:

Treatment of TMG should be decided on:

Drug Regimens

Pharmacological medical therapy for toxic multinodular goiter is primarily based on beta blockers and anti-thyroid drugs.[4]

  1. Toxic Multinodular Goiter
    • Hyperthyroidism[5]
    • Subclinical hyperthyroidism with comorbid conditions such as diabetes mellitus, heart failure or CNS abnormality[3]
      • Preferred regimen (1): Propylthiouracil 5-10 mg q24h PO for long term to avoid remission with 3 month review of TSH
      • Alternative regimen (1): Methimazole 5-10 mg q24h PO for long term to avoid remission with 3 month review of TSH
    • Subclinical hyperthyroidism without comorbid conditions
      • Preferred: Monitoring/Review of TSH every 3 month
      • Alternative regimen (1):Propylthiouracil 5-10 mg q24h PO for long term to avoid remission with review of TSH every 3 month

Ultrasound-Guided percutaneous ethanol injection (PEI):[6]

References

References

  1. ↑ 1.0 1.1 Laurberg P, Buchholtz Hansen PE, Iversen E, Eskjaer Jensen S, Weeke J (1986). “Goitre size and outcome of medical treatment of Graves’ disease”. Acta Endocrinol (Copenh). 111 (1): 39–43. PMID 3753814.
  2. ↑ name=”pmid1283983″>van Soestbergen MJ, van der Vijver JC, Graafland AD (1992). “Recurrence of hyperthyroidism in multinodular goiter after long-term drug therapy: a comparison with Graves’ disease”. J Endocrinol Invest. 15 (11): 797–800. doi:10.1007/BF03348807. PMID 1283983.
  3. ↑ 3.0 3.1 Becker DV, Hurley JR (1971). “Complications of radioiodine treatment of hyperthyroidism”. Semin Nucl Med. 1 (4): 442–60. PMID 4107462.
  4. ↑ Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL; et al. (2016). “2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis”. Thyroid. 26 (10): 1343–1421. doi:10.1089/thy.2016.0229. PMID 27521067.
  5. ↑ van Soestbergen MJ, van der Vijver JC, Graafland AD (1992). “Recurrence of hyperthyroidism in multinodular goiter after long-term drug therapy: a comparison with Graves’ disease”. J Endocrinol Invest. 15 (11): 797–800. doi:10.1007/BF03348807. PMID 1283983.
  6. ↑ Felício JS, Conceição AM, Santos FM, Sato MM, Bastos Fde A, Braga de Souza AC; et al. (2016). “Ultrasound-Guided Percutaneous Ethanol Injection Protocol to Treat Solid and Mixed Thyroid Nodules”. Front Endocrinol (Lausanne). 7: 52. doi:10.3389/fendo.2016.00052. PMC 4893597. PMID 27375551.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sunny Kumar MD [2],Furqan M M. M.B.B.S[3]